Back to Research Home
BTIBritish American Tobacco p.l.c.
Health Care · Medicinal Chemicals and Botanical Products · Large
$59.48−1.64%
As of 23 Oct 2026Mkt cap $120B
Stage 13
AVOID
Fundamentals
29.1/75
Technical
9.4/15
Independent
38.5/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +6.2%
- 3M
- −2.2%
- 6M
- +2.4%
- 1Y
- +16.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 9.9%
- Operating margin
- 10.6%
- FCF margin
- 22.6%
- Current ratio
- 0.9x
Growth
- Revenue growth
- +2.1%Latest FY YoY
- Revenue CAGR
- −1.1%
- EPS CAGR
- +3.2%
- FCF CAGR
- −11.8%
Capital
- Share-count trend
- −0.7%3Y annualised
- Net debt
- $42.1B5.0x OCF
Annual trend
- CAGR 2021–2025
- −1.1%
- Latest · 2025
- $34B
- YoY
- +2.1%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-02-11
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- stale
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded